Elizabeth M Sagatys1, Ling Zhang. 1. Department of Hematopathology and Laboratory Medicine, Moffitt Cancer Center, Tampa, FL 33612, USA.
Abstract
BACKGROUND: The clinical course of patients with chronic lymphocytic leukemia (CLL) is heterogeneous, with some patients experiencing rapid disease progression and others living for decades without requiring treatment. The Rai and Binet clinical staging systems are used to define disease extent and predict survival. The pathology laboratory also provides important prognostic information. METHODS: A review of the literature was performed on the subject of staging in CLL from clinical and pathologic standpoints. This article also reviews currently available diagnostic approaches related to disease prognosis and to timing of treatment and follow-up in patients with CLL. RESULTS: Novel biological and cytogenetic features such as immunoglobulin heavy-chain variable gene segment [IgVH], genomic aberrations including del(17p13), del(11q23), del(13q14), and trisomy 12, serum markers (thymidine kinase and beta-2 microglobulin), and cellular markers (CD38 and ZAP70) have become increasingly important in predicting prognosis at the time of diagnosis. CONCLUSIONS: Current prognostic factors directly or indirectly influence the management of patients with CLL and help to predict treatment-free and overall survival.
BACKGROUND: The clinical course of patients with chronic lymphocytic leukemia (CLL) is heterogeneous, with some patients experiencing rapid disease progression and others living for decades without requiring treatment. The Rai and Binet clinical staging systems are used to define disease extent and predict survival. The pathology laboratory also provides important prognostic information. METHODS: A review of the literature was performed on the subject of staging in CLL from clinical and pathologic standpoints. This article also reviews currently available diagnostic approaches related to disease prognosis and to timing of treatment and follow-up in patients with CLL. RESULTS: Novel biological and cytogenetic features such as immunoglobulin heavy-chain variable gene segment [IgVH], genomic aberrations including del(17p13), del(11q23), del(13q14), and trisomy 12, serum markers (thymidine kinase and beta-2 microglobulin), and cellular markers (CD38 and ZAP70) have become increasingly important in predicting prognosis at the time of diagnosis. CONCLUSIONS: Current prognostic factors directly or indirectly influence the management of patients with CLL and help to predict treatment-free and overall survival.
Authors: Nataly Cruz-Rodriguez; Alba L Combita; Leonardo J Enciso; Lauren F Raney; Paula L Pinzon; Olga C Lozano; Alba M Campos; Niyireth Peñaloza; Julio Solano; Maria V Herrera; Jovanny Zabaleta; Sandra Quijano Journal: J Exp Clin Cancer Res Date: 2017-02-28
Authors: Soo Jin Seung; Manjusha Hurry; Shazia Hassan; Ashlie Elnoursi; Krystin A B Scheider; Dennis Wagner; Jonathan J Edwin; Andrew T W Aw Journal: Curr Oncol Date: 2021-11-19 Impact factor: 3.677
Authors: Eszter Szánthó; Harjit Pal Bhattoa; Mária Csobán; Péter Antal-Szalmás; Anikó Újfalusi; János Kappelmayer; Zsuzsanna Hevessy Journal: PLoS One Date: 2014-03-12 Impact factor: 3.240
Authors: Enaam Abdelrhman Abdelgader; Nada Hassan Eltayeb; Tasniem Ahmed Eltahir; Osama Ali Altayeb; Eman Abbass Fadul; Eldirdiri M Abdel Rahman; Tarig H Merghani Journal: BMC Res Notes Date: 2018-11-15